Create a narrative

Curis Community

NasdaqCM:CRIS Community

1 Narratives written by author
0 Comments on narratives written by author
3 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

FDA And EMA Will Accelerate Emavusertib Clinical Trials

Key Takeaways Feedback from regulatory bodies can expedite market entry for emavusertib, potentially accelerating revenue and competitive advantage in the CNS lymphoma space. Financial stability is bolstered by extended cash runway, allowing Curis to sustain operations and invest in R&D for pipeline advancement.

US$16.00

FV

86.3% undervalued

33.19%

Revenue growth p.a.

0

0

2

7 days ago